RT Journal Article
SR Electronic
T1 Comment on “Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells”
JF Science Translational Medicine
FD American Association for the Advancement of Science
SP 188le2
OP 188le2
DO 10.1126/scitranslmed.3005065
VO 5
IS 188
A1 Bilican, Bilada
A1 Serio, Andrea
A1 Barmada, Sami J.
A1 Nishimura, Agnes Lumi
A1 Sullivan, Gareth J.
A1 Carrasco, Monica
A1 Phatnani, Hemali P.
A1 Puddifoot, Clare A.
A1 Story, David
A1 Fletcher, Judy
A1 Park, In-Hyun
A1 Friedman, Brad A.
A1 Daley, George Q.
A1 Wyllie, David J. A.
A1 Hardingham, Giles E.
A1 Wilmut, Ian
A1 Finkbeiner, Steven
A1 Maniatis, Tom
A1 Shaw, Christopher E.
A1 Chandran, Siddharthan
YR 2013
UL http://stm.sciencemag.org/content/5/188/188le2.abstract
AB Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.